Jeffrey M. Conroy

Publications:

August 23, 2024 Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
June 20, 2024 Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
June 2, 2024 Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer suggests a mechanism of immune evasion and tumor progression
June 2, 2024 Novel HLA-Ilo/HLA-IIhi phenotype suggests pattern of immune evasion in triple-negative breast cancer
June 1, 2024 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability
April 30, 2024 Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
March 20, 2024 OX40/OX40 Ligand and its Role in Precision Immune Oncology
March 19, 2024 The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
February 5, 2024 Automated Tissue Dissection Solution to Support Comprehensive Genomic and Immune Profiling
September 23, 2023 PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
August 8, 2023 T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
June 12, 2023 LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
June 6, 2023 Sex-specific effects of body composition on tumor microenvironment in non–small cell lung cancer
June 6, 2023 The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC)
May 26, 2023 Association of antifolate response signature status and clinical activity of pemetrexed platinum chemotherapy in non-small cell lung cancer - The Piedmont Study
May 8, 2023 RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
March 21, 2022 Cancer testis antigen burden: pan-cancer distribution and survival implications
October 30, 2024 Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
October 29, 2024 A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
April 7, 2024 Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
April 7, 2024 Landscape of TIGIT and PD-L1 co-expression in solid tumors
February 12, 2024 Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
February 5, 2024 Fully Automated Extraction of High-Quality Total Nucleic Acids from FFPE Specimens using Covaris truXTRAC® FFPE SMART Solutions & Hamilton Robotics
February 5, 2024 Implementation of Laboratory Automation to Support Scaling of Cancer Patients Testing using OmniSeq® INSIGHT Molecular Diagnostic Test
January 30, 2024 LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
January 13, 2024 Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity
December 11, 2023 Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
December 11, 2023 Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
November 17, 2023 Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
November 17, 2023 Genomic stability of prostate cancers with homologous recombination gene alterations
November 17, 2023 Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
November 17, 2023 Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
November 17, 2023 LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
November 17, 2023 A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
November 4, 2023 Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
November 3, 2023 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
November 3, 2023 Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo
November 3, 2023 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
November 3, 2023 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
November 3, 2023 Immune microenvironment of primary versus metastatic melanoma of the brain
November 3, 2023 Metastatic triple negative breast cancer has distinct tumor immune landscape
November 1, 2023 Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
September 1, 2022 Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
March 1, 2022 Checkpoint coexpression landscape in gastroesophageal adenocarcinoma
January 1, 2018 Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors
February 14, 2024 Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer